Abstract
As MRSA are considered Staphylococcus aureus isolates with oxacillin minimum inhibitory concentration (MIC) of ≥4 mg/L or harboring the mecA gene. However, the presence of mecA does not necessarily lead to oxacillin resistance and mecA gene-carrying isolates may have oxacillin MIC within the susceptible range (≥2 mg/L). During the last few years it has become apparent that oxacillin-susceptible (OS) mecA-positive S. aureus isolates (commonly called OS-MRSA) are rather commonly detected worldwide and may remain undiagnosed using phenotypic susceptibility testing methods. This review will summarize the current reports on OS-MRSA isolations and the underlying mechanisms regulating the expression of oxacillin resistance and also oxacillin susceptibility in mecA-positive S. aureus isolates. As MRSA commonly cause severe infections against which effective therapies are limited, understanding of these mechanisms could enable the identification of new targets for the treatment or reversion of the MRSA phenotype.
Keywords: FemXAB, OS-MRSA, heterogeneity, community-associated MRSA, PBP2a, molecular detection.
Current Pharmaceutical Design
Title:Driving Forces of Mechanisms Regulating Oxacillin-Resistance Phenotypes of MRSA: Truly Oxacillin-Susceptible mecA-Positive Staphylococcus aureus Clinical Isolates also Exist
Volume: 21 Issue: 16
Author(s): Spyros Pournaras, Artur J. Sabat, Hajo Grundmann, Ron Hendrix, Athanasios Tsakris and Alexander W. Friedrich
Affiliation:
Keywords: FemXAB, OS-MRSA, heterogeneity, community-associated MRSA, PBP2a, molecular detection.
Abstract: As MRSA are considered Staphylococcus aureus isolates with oxacillin minimum inhibitory concentration (MIC) of ≥4 mg/L or harboring the mecA gene. However, the presence of mecA does not necessarily lead to oxacillin resistance and mecA gene-carrying isolates may have oxacillin MIC within the susceptible range (≥2 mg/L). During the last few years it has become apparent that oxacillin-susceptible (OS) mecA-positive S. aureus isolates (commonly called OS-MRSA) are rather commonly detected worldwide and may remain undiagnosed using phenotypic susceptibility testing methods. This review will summarize the current reports on OS-MRSA isolations and the underlying mechanisms regulating the expression of oxacillin resistance and also oxacillin susceptibility in mecA-positive S. aureus isolates. As MRSA commonly cause severe infections against which effective therapies are limited, understanding of these mechanisms could enable the identification of new targets for the treatment or reversion of the MRSA phenotype.
Export Options
About this article
Cite this article as:
Pournaras Spyros, Sabat J. Artur, Grundmann Hajo, Hendrix Ron, Tsakris Athanasios and Friedrich W. Alexander, Driving Forces of Mechanisms Regulating Oxacillin-Resistance Phenotypes of MRSA: Truly Oxacillin-Susceptible mecA-Positive Staphylococcus aureus Clinical Isolates also Exist, Current Pharmaceutical Design 2015; 21 (16) . https://dx.doi.org/10.2174/1381612821666150310103754
DOI https://dx.doi.org/10.2174/1381612821666150310103754 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Human Microbiome Project, Personalized Medicine and the Birth of Pharmacomicrobiomics
Current Pharmacogenomics and Personalized Medicine Perceval Sutureless Valve – are Sutureless Valves Here?
Current Cardiology Reviews The Development of Antimicrobial Peptides as New Antibacterial Drugs
Current Protein & Peptide Science High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders
Current HIV Research Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Antibacterial Function of the Human Cathelicidin-18 Peptide (LL-37) between Theory and Practice
Protein & Peptide Letters Non-Steroidal Targets in the Diagnosis and Treatment of Endometriosis
Current Medicinal Chemistry Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis
Current Cardiology Reviews Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy Current Developments in Anti-Fungal Agents
Current Medicinal Chemistry - Anti-Infective Agents Use of Natural Antimicrobials from a Food Safety Perspective for Control of Staphylococcus aureus
Current Pharmaceutical Biotechnology Bacteriophages and Phage-Derived Proteins – Application Approaches
Current Medicinal Chemistry An Update to Enterococcal Bacteremia: Epidemiology, Resistance, and Outcome
Infectious Disorders - Drug Targets Novel Perspective for Antithrombotic Therapy in TAVI
Current Pharmaceutical Design Medicinal Use of Lincosamides and Microbial Resistance to Them
Anti-Infective Agents in Medicinal Chemistry Biofilms: An Extra Hurdle for Effective Antimicrobial Therapy
Current Pharmaceutical Design The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets Biofilms in Skin Infections: Propionibacterium acnes and Acne Vulgaris
Infectious Disorders - Drug Targets Heart Failure in South America
Current Cardiology Reviews Antibacterial Combination of Oleoresin from Copaifera multijuga Hayne and Biogenic Silver Nanoparticles Towards Streptococcus agalactiae
Current Pharmaceutical Biotechnology